Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryu Watanabe

Showing results (121-130 of 158) with videos related to

Pageof 16
Sort By:
Journal of Internal Medicine|September 22, 2025
Long-term efficacy of rituximab versus intravenous cyclophosphamide for severe ANCA-associated vasculitis in multicenter REVEAL cohort studyShogo Matsuda, Takuya Kotani, Daisuke Nishioka, et al.
Modern Rheumatology|December 12, 2025
Rituximab versus intravenous cyclophosphamide for anti-neutrophil cytoplasmic antibody-associated vasculitis with severe renal impairment: a multicentre REVEAL cohort studyHirofumi Miyake, Ayana Okazaki, Shogo Matsuda, et al.
BMC Rheumatology|May 14, 2026
Personalized exercise therapy during targeted drug therapy tapering in patients with rheumatoid arthritis: a pilot randomized controlled trialShinsuke Yamada, Akira Onishi, Takumi Imai, et al.
Modern Rheumatology|December 15, 2021
The real-world effectiveness of anti-RANKL antibody denosumab on the clinical fracture prevention in patients with rheumatoid arthritis: The ANSWER cohort studyKoichi Murata, Ryuji Uozumi, Motomu Hashimoto, et al.
Arthritis Research & Therapy|March 7, 2025
Comparative effectiveness of subcutaneous sarilumab 200 mg biweekly, subcutaneous Tocilizumab 162 mg biweekly, and intravenous Tocilizumab 8 mg/kg every 4 weeks in patients with rheumatoid arthritis: a prospective cohort studyAkira Onishi, Masao Tanaka, Takayuki Fujii, et al.
Modern Rheumatology|June 10, 2023
Pathogenicity of IgG-Fc desialylation and its association with Th17 cells in an animal model of systemic lupus erythematosusYuri Nishida, Mirei Shirakashi, Noritaka Hashii, et al.
Arthritis Research & Therapy|March 28, 2021
Urinary sodium-to-potassium ratio associates with hypertension and current disease activity in patients with rheumatoid arthritis: a cross-sectional studyHiroto Minamino, Masao Katsushima, Motomu Hashimoto, et al.
Rheumatology (Oxford, England)|September 9, 2024
Association of gut commensal translocation with autoantibody production in systemic lupus erythematosusMasao Katsushima, Yoichi Nakayama, Tsuneyasu Yoshida, et al.
Modern Rheumatology|September 16, 2022
Systematic review and meta-analysis for 2023 clinical practice guidelines of the Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis for the management of ANCA-associated vasculitisRyu Watanabe, Megumi Oshima, Norihiro Nishioka, et al.
Modern Rheumatology|January 21, 2023
Factors associated with osteoporosis and fractures in patients with systemic lupus erythematosus: Kyoto Lupus CohortTomoya Nakajima, Hiroshi Doi, Ryu Watanabe, et al.
Pageof 16

Showing results (121-130 of 158) with videos related to

Sort By:
Pageof 16
Journal of Internal Medicine|September 22, 2025
Long-term efficacy of rituximab versus intravenous cyclophosphamide for severe ANCA-associated vasculitis in multicenter REVEAL cohort studyShogo Matsuda, Takuya Kotani, Daisuke Nishioka, et al.
Modern Rheumatology|December 12, 2025
Rituximab versus intravenous cyclophosphamide for anti-neutrophil cytoplasmic antibody-associated vasculitis with severe renal impairment: a multicentre REVEAL cohort studyHirofumi Miyake, Ayana Okazaki, Shogo Matsuda, et al.
BMC Rheumatology|May 14, 2026
Personalized exercise therapy during targeted drug therapy tapering in patients with rheumatoid arthritis: a pilot randomized controlled trialShinsuke Yamada, Akira Onishi, Takumi Imai, et al.
Modern Rheumatology|December 15, 2021
The real-world effectiveness of anti-RANKL antibody denosumab on the clinical fracture prevention in patients with rheumatoid arthritis: The ANSWER cohort studyKoichi Murata, Ryuji Uozumi, Motomu Hashimoto, et al.
Arthritis Research & Therapy|March 7, 2025
Comparative effectiveness of subcutaneous sarilumab 200 mg biweekly, subcutaneous Tocilizumab 162 mg biweekly, and intravenous Tocilizumab 8 mg/kg every 4 weeks in patients with rheumatoid arthritis: a prospective cohort studyAkira Onishi, Masao Tanaka, Takayuki Fujii, et al.
Modern Rheumatology|June 10, 2023
Pathogenicity of IgG-Fc desialylation and its association with Th17 cells in an animal model of systemic lupus erythematosusYuri Nishida, Mirei Shirakashi, Noritaka Hashii, et al.
Arthritis Research & Therapy|March 28, 2021
Urinary sodium-to-potassium ratio associates with hypertension and current disease activity in patients with rheumatoid arthritis: a cross-sectional studyHiroto Minamino, Masao Katsushima, Motomu Hashimoto, et al.
Rheumatology (Oxford, England)|September 9, 2024
Association of gut commensal translocation with autoantibody production in systemic lupus erythematosusMasao Katsushima, Yoichi Nakayama, Tsuneyasu Yoshida, et al.
Modern Rheumatology|September 16, 2022
Systematic review and meta-analysis for 2023 clinical practice guidelines of the Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis for the management of ANCA-associated vasculitisRyu Watanabe, Megumi Oshima, Norihiro Nishioka, et al.
Modern Rheumatology|January 21, 2023
Factors associated with osteoporosis and fractures in patients with systemic lupus erythematosus: Kyoto Lupus CohortTomoya Nakajima, Hiroshi Doi, Ryu Watanabe, et al.
Pageof 16